IRIS
PITINI, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.741
NA - Nord America 4.997
AS - Asia 2.772
SA - Sud America 991
AF - Africa 85
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.933
RU - Federazione Russa 2.929
SG - Singapore 1.199
BR - Brasile 863
CN - Cina 823
IE - Irlanda 711
SE - Svezia 694
UA - Ucraina 344
HK - Hong Kong 312
DE - Germania 288
GB - Regno Unito 167
FR - Francia 152
FI - Finlandia 150
IT - Italia 140
VN - Vietnam 136
IN - India 63
BD - Bangladesh 45
AR - Argentina 41
BE - Belgio 39
IQ - Iraq 29
ZA - Sudafrica 28
MX - Messico 27
TR - Turchia 25
PL - Polonia 24
EC - Ecuador 21
NL - Olanda 21
CA - Canada 20
JP - Giappone 19
CZ - Repubblica Ceca 18
VE - Venezuela 17
AT - Austria 16
UZ - Uzbekistan 16
CO - Colombia 15
KE - Kenya 12
MA - Marocco 12
AZ - Azerbaigian 11
PY - Paraguay 11
TN - Tunisia 11
ES - Italia 10
PK - Pakistan 10
IL - Israele 8
PE - Perù 8
CL - Cile 7
ID - Indonesia 7
IR - Iran 7
PH - Filippine 7
AE - Emirati Arabi Uniti 6
LT - Lituania 6
OM - Oman 6
SA - Arabia Saudita 6
BO - Bolivia 5
EG - Egitto 5
JO - Giordania 5
AM - Armenia 4
AU - Australia 4
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
NO - Norvegia 4
PA - Panama 4
PS - Palestinian Territory 4
AL - Albania 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
LB - Libano 3
LV - Lettonia 3
NP - Nepal 3
QA - Qatar 3
BA - Bosnia-Erzegovina 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BG - Bulgaria 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LS - Lesotho 1
Totale 14.582
Salva come PNG Salva come JPEG
Città #
Moscow 788
Dublin 711
Ashburn 703
Singapore 674
Jacksonville 653
Chandler 567
Dallas 450
Nyköping 358
Hong Kong 310
Beijing 307
San Jose 185
Ann Arbor 156
The Dalles 140
Princeton 123
Cambridge 119
Los Angeles 112
Des Moines 101
Lauterbourg 100
Dearborn 93
Medford 86
Boardman 70
New York 68
Lancaster 61
Woodbridge 60
Munich 59
São Paulo 58
Messina 55
Buffalo 53
Tianjin 46
Ho Chi Minh City 41
Wilmington 39
Brussels 37
Guangzhou 36
Jinan 36
Orem 31
Hanoi 29
Redondo Beach 28
Rio de Janeiro 27
Shenyang 26
Houston 25
Council Bluffs 22
San Mateo 22
Turku 22
Seattle 21
Warsaw 21
Chicago 20
Santa Clara 20
Belo Horizonte 19
Tokyo 18
Nanjing 17
Ningbo 17
Shanghai 17
Brno 16
Denver 16
Düsseldorf 16
Haikou 16
Atlanta 15
Brasília 15
Chennai 15
Zhengzhou 15
Nanchang 14
Vienna 14
Auburn Hills 13
Frankfurt am Main 13
Stockholm 13
Taizhou 13
Tashkent 13
Baghdad 12
Goiânia 12
Hangzhou 12
Hebei 12
Salvador 12
Amsterdam 11
Baku 11
Brooklyn 11
Curitiba 11
Johannesburg 11
Quito 11
Boston 10
Campinas 10
Phoenix 10
Porto Alegre 10
Shenzhen 10
Buenos Aires 9
Dhaka 9
Hyderabad 9
Montreal 9
Ribeirão Preto 9
San Francisco 9
Barnet 8
Cape Town 8
Manaus 8
Nairobi 8
Paris 8
Pune 8
Santo André 8
Bologna 7
Bremen 7
Caracas 7
Haiphong 7
Totale 8.388
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 233
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 215
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 209
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 201
An accessory spleen wrongly recognised as relapse by positron emission tomography 192
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 190
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 186
CLINICAL ACTIVITY OF BORTEZOMIB IN RELAPSED OR REFRACTORY GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT TYPE 184
An acute-leukaemia-like picture due to breast carcinoma cells. 184
AMIFOSTINE IN CONJUCTION WITH H.D. VP16 AND G-CSF ENABLE PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 182
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 180
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report 178
Effect of treatment with amifostine in patients with myelodisplastic syndromes on clinical outcome and apoptosis in bone marrow 177
Emerging markers of cachexia predict survival in cancer patients. 175
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas 175
Trattamento endoscopico scleroterapico nelle neoplasie sanguinanti del tratto digestivo. 174
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 172
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 172
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 171
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 169
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 163
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 162
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 162
A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular remission in chronic lymphocytic leukaemia 160
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 160
ANCHE IN VIVO IL PAMIDRONATO E' UN INDUTTORE DELLA APOPTOSI NELLE PLASMACELLULE MIELOMATOSE 160
Fatal delayed diagnosis in a patient with falciparum malaria 156
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 155
Endobronchial electrocautery for the dehydration of lung cancer. 155
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 153
AN UNUSUAL PRESENTATION OF SCHISTOSOMIASIS 152
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 152
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 151
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients 150
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 146
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes 144
Thyroid function, autoimmunity and nodules in hematological malignancies 144
IMATINIB-INDUCED APOPTOSIS IN EOSINOPHILS OF PATIENTS WITH A HYPEREOSINOPHILIC SYNDROME PREDICTS RESPONSE TO TREATMENT 141
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 141
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 140
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 140
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 137
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report 136
Use of bisphosphonates in oncology 135
Temozolomide-induced shrinkage of a pituitary carcinoma. 134
Circulating plasma cells in Multiple Myeloma: correlation with disease stage 133
How cells respond to interferons. 131
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 130
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 129
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 129
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 127
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient 127
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF 126
ADVERSE PROGNOSTIC FACTOR OF p53 GENE DELECTION DETECTED BY FISH IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION 124
ANALISI SEQUENZIALE DELLA TRISOMIA 12 NELLA LEUCEMIA LINFATICA CRONICA 121
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 120
ALTE DOSI: QUESTIONI APERTE E SVILUPPI FUTURI 119
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma 118
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 118
IMMUNOCHEMOTHERAPY WITH RITUXIMAB AND TEMOZOLOMIDE FOR CENTRAL NERVOUS SYSTEM LYMPHOMAS 117
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 117
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 116
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 115
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 115
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 114
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 113
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 113
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 111
DIABETIC FOOT DISEASE IN A PATIENT WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE 106
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 106
Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a patient with breast cancer 103
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease 102
Pitfalls of positron emission tomography for assessing relapse in Hodgkin'sdisease: a case report 99
null 99
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 98
Sequential treatment with alemtuzumab and rituximab can induce long-term responses in splenic marginal zone lymphoma 92
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS 91
SUCCESSFULL MOBILIZATION OF PERIPHERAL PROGENITOR CELLS WITH PACLITAXEL AND LENOGRASTIM PATIENTS WITH METASTATIC BREAST CANCER 91
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence 91
null 90
Uso di Bortezomib come terapia di prima linea nella leucemia plasmacellulare primaria 89
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. 88
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 88
PIK3CA mutations in breast cancer: A potential predictive marker 87
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 86
ERYTHROPOIETIN IN CONJUNCTION WITH H.D. VP16 AND LENOGRASTIM ENABLE PBPC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 86
Risk of second malignant neoplasm among patients with lymphoma 85
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 85
ERYTHROPOIETIN IN COMBINATION WITH LENOGRASTIM AFTER CYCLOPHOSPHAMIDE IMPROVES PERIPHERAL BLOOD PROGENITOR CELL YIELD IN MULTIPLE MYELOMA PATIENT 84
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate. 84
Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. 84
Single-dose of pegfilgrastim after chemotherapy is sufficient for mobilization of peripheral blood stem cells in patients with multiple myeloma 83
RESPONSE TO IMATINIB IN CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACTIVATION OF THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR (PDGF betaR) 83
IMPIEGO DELLA AMIFOSTINA NELLE PROCEDURE DI MOBILIZZAZIONE. NOSTRA ESPERIENZA 83
LONG-TERM RESULTS FROM MOPPEBVCAD CHEMOTHERAPY WITH OPTIONAL LIMITED RADIOTHERAPY IN ADVANCED HODGKIN'S DISEASE 83
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 83
Single-dose pegfilgrastim after chemotherapy is sufficient for mobilisation of peripheral blood stem cells in patients with multiple myeloma 82
Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab 82
IMPIEGO DELLA AMIFOSTINE+HD VP16+G-CSF NEI PAZIENTI CON MIELOMA MULTIPLO CHE NON MOBILIZZANO DOPO CTX+G-CSF 82
THALIDOMIDE IN COMBINATION WITH DCEP OVERCOMES VAD CHEMORESISTENCE AND ALLOWS PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS 82
Totale 13.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021174 0 0 0 0 0 0 0 0 0 89 57 28
2021/2022848 6 139 18 17 25 3 58 27 5 160 154 236
2022/20232.164 173 209 102 170 187 205 23 136 855 9 71 24
2023/2024445 38 88 29 57 28 83 14 34 3 22 3 46
2024/20252.370 28 34 31 145 106 71 33 597 606 156 183 380
2025/20266.307 325 390 478 362 535 1.460 878 787 897 195 0 0
Totale 14.725